ANTI-SCARRING

GENE THERAPY

The future is here

Tcellexa ECHNOLOGY

CELLEXA GENE THERAPY

Cellastra is piondering

I'm a paragraph. Click here to add your own text and edit me. It's easy.

CELLEXA is a proprietary gene vector suitable for human use

Applied in the wound CELLEXA delivers the genetic code for expression and production of anti scarring peptides at the site of injury

Get In Touch

CLX-003

CLX-003 is a formulation for injection after after back surgery (spinal laminectomy) or for prevention of intrabdominal adhesions after abdominal or gynecological surgery.

HOW DOES IT WORK?

CELLLEXA is a formulation of an effective transport vehicle (viral vector)
Programmed with the genetic code for a lactoferrin derived anti-scarring peptide.
Applied on top of he skin or by injection CELLEXA delivers the code to the targeted cells.
IEnables continuous production of anti-scarring peptides in the cells of the wound area for many weeks or months.

THE PEPTIDE DISRUPTS ROOT CAUSES OF SCARRING

CELLEXA (CLX-001)

CLX-001 is gene therapy to prevent scarring after burn injury..

Applied topically by spray or ointment suitable for larger body surface area.

CLX-002

CXL-002 for prevention of dermal scarring after surgery. Applied as gel before wound closure or injected subcuteneously into the wound area in cosmetically challening areas such as the face, mammoplasty or after C-section..

Portfolio:

1. CONTROLS INFLAMMATION

inflammation promotes severe scarring

2. STIMULATES FIBRINOLYSIS

Bottom: Blocked fibrinolysis promotes scarring.

Top: Reduced blocking increases fibrinolysis and scar resolution

3. FIGHTS INFECTION

infections cause inflammation which increases scar formation